National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) : human isolates final report, 2005
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) : human isolates final report, 2005

Filetype[PDF-1.19 MB]


English
Details You May Also Like

Details:

  • Alternative Title:
    NARMS
  • Corporate Authors:
  • Description:
    The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and U.S. Department of Agriculture (USDA). The primary purpose of NARMS at CDC is to monitor antimicrobial resistance among foodborne enteric bacteria isolated from humans. Other components of the interagency NARMS program include surveillance for resistance in human enteric bacterial pathogens isolated from foods, conducted by the FDA Center for Veterinary Medicine (http://www.fda.gov/cvm/narms_pg.html), and resistance in human enteric pathogens isolated from animals, conducted by the USDA Agricultural Research Services (http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08).

    Many NARMS activities are conducted within the framework of CDC’s Emerging Infections Program (EIP), Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network (FoodNet). In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also includes public health research into the mechanisms of resistance, education efforts to promote prudent use of antimicrobial agents, and studies of resistance in commensal organisms.

    Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella and Escherichia coli O157 isolates in 14 sites. In 1997, testing of clinical Campylobacter isolates was initiated in the five sites participating in FoodNet. Testing of clinical Salmonella Typhi and Shigella isolates was added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, Salmonella Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states have been participating in Campylobacter surveillance.

    This annual report includes CDC’s surveillance data for 2005 for clinical non-Typhi Salmonella, Salmonella Typhi, Shigella, and E. coli O157 isolates. Resistance trends and comparisons with previous years are included when appropriate. Antimicrobial subclasses defined by CLSI are used in data presentation and analysis. CLSI subclasses constitute major classifications of antimicrobial agents, e.g., aminoglycosides and cephalosporins.

    Suggested citation: CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2005. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2008.

  • Subjects:
  • Document Type:
    Report
  • Place as Subject:
    United States
  • Pages in Document:
    77 numbered pages
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov